FDA Approved Antibody-based Therapeutics
Antibody Target: Antibody Type Indication Company Approval Date Rituxan: Rituximab CD20:Chimeric, IgG1 Cancer Genentech 1997 (US) 1998 (EU) Herceptin: Trastuzumab HER2:Humanized, IgG1 Cancer Genentech/ Roche 1998 (US) 2000 (EU) *Mylotarg: Gemtuzumab ozogamicin CD33:Humanized, IgG4, immunotoxin Cancer Wyeth/Pfizer 2000 (US) Campath: Alemtuzumab CD52:Humanized, IgG1 Cancer Genzyme 2001 (US) 2001 (EU) Zevalin: Ibritumomab tiuxetan CD20: Murine, IgG1, radiolabeled (Yttrium 90) Cancer Biogen Idec 2002 (US) 2004 (EU) Bexxar: Tositumomab-I-131 CD20: Murine, IgG2a, radiolabeled (Iodine 131) Cancer Corixa/GSK 2003 (US) Erbitux:Cetuximab EGFR: Chimeric, IgG1 Cancer Imclone/Lilly 2004 (US) 2004 (EU) Avastin:Bevacizumab VEGF: Humanized, IgG1 Cancer Genentech/ Roche 2004 (US) 2005 (EU) Vectibix:Panitumumab EGFR: Human, IgG2 Cancer Amgen 2006 (US) Arzerra:Ofatumumab CD20: Human IgG1 Cancer Genmab 2009 (EU) Yervoy:Ipilimumab CTLA-4: Human IgG1 Cancer BMS 2011 (US) Adcetris:Brentuximab Vedotin CD30: Chimeric IgG1 Drug-conjugate Cancer Seattle Genetics 2011 (US)
'림프종관련 > 의학자료' 카테고리의 다른 글
| [스크랩] 혈액의 구성과 기능 (0) | 2012.11.09 |
|---|---|
| [스크랩] 혈액의 순환 해부학 (0) | 2012.11.09 |
| 표면 분화 항원(CD; Cluster of Differentiation) (0) | 2012.11.07 |
| Classical Hodgkin Lymphoma와 관련된 CD 항원 (0) | 2012.11.06 |
| CD 항원(CD1 ~ CD50) (0) | 2012.11.05 |